Shire announces changes at the top

Share this article:
Shire CEO Matthew Emmens
Shire CEO Matthew Emmens

Shire announced succession plans today under which Dr. James Cavanaugh will step down as chairman in June and CEO Matthew Emmens will succeed him as non-executive chairman.

Also next June, Angus Russell will take over for Emmens as CEO and David Kappler will become deputy chairman while continuing in his existing role as senior independent director.
 
The changes will be made official at Shire's annual general meeting to be held next summer.

Emmens joined Shire in 2003. His successor Russell has been CFO since 1999 and has 27 years experience in the pharmaceutical industry including working for ICI, Zeneca and AstraZeneca in finance, strategy and marketing. Throughout his time with Shire, Russell has been a lead member of the Shire Management Committee that devised and implemented Shire's long-term focused business strategy. Shire will now work to identify a replacement CFO in order to ensure an orderly succession, the company said in a statement.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...